Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karine Lafleur

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Molecular Graphics & Modelling|October 2, 2010
Complementing ultrafast shape recognition with an optical isomerism descriptorTing Zhou, Karine Lafleur, Amedeo Caflisch
Journal of Medicinal Chemistry|October 1, 2009
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)Karine Lafleur, Danzhi Huang, Ting Zhou, et al.
Journal of Medicinal Chemistry|December 21, 2012
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallographyKarine Lafleur, Jing Dong, Danzhi Huang, et al.
Bioinformatics (Oxford, England)|November 28, 2009
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysisDanzhi Huang, Ting Zhou, Karine Lafleur, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamicsHongtao Zhao, Jing Dong, Karine Lafleur, et al.
Journal of Medicinal Chemistry|July 31, 2014
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validationAndrea Unzue, Jing Dong, Karine Lafleur, et al.
European Journal of Medicinal Chemistry|February 25, 2016
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validationAndrea Unzue, Karine Lafleur, Hongtao Zhao, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Molecular Graphics & Modelling|October 2, 2010
Complementing ultrafast shape recognition with an optical isomerism descriptorTing Zhou, Karine Lafleur, Amedeo Caflisch
Journal of Medicinal Chemistry|October 1, 2009
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)Karine Lafleur, Danzhi Huang, Ting Zhou, et al.
Journal of Medicinal Chemistry|December 21, 2012
Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallographyKarine Lafleur, Jing Dong, Danzhi Huang, et al.
Bioinformatics (Oxford, England)|November 28, 2009
Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysisDanzhi Huang, Ting Zhou, Karine Lafleur, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamicsHongtao Zhao, Jing Dong, Karine Lafleur, et al.
Journal of Medicinal Chemistry|July 31, 2014
Pyrrolo[3,2-b]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: structure-based design, synthesis, and in vivo validationAndrea Unzue, Jing Dong, Karine Lafleur, et al.
European Journal of Medicinal Chemistry|February 25, 2016
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validationAndrea Unzue, Karine Lafleur, Hongtao Zhao, et al.
Pageof 1